XHKG
2161
Market cap169mUSD
Oct 06, Last price
1.63HKD
1D
0.62%
1Q
-22.01%
IPO
-42.81%
Name
JBM (Healthcare) Ltd
Chart & performance
P/E
6.62
P/S
1.60
EPS
0.25
Div yield, %
13.04%
Shrs. gr., 5y
-1.79%
Rev. gr., 5y
16.01%
Revenues
835m
+6.69%
Net income
201m
+1.94%
CFO
153m
-32.73%
Dividend
Sep 07, 20260.0735 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
JBM (Healthcare) Limited functions as an investment holding company that operates across Asia, engaging in the entire process of bringing healthcare and wellness products to market, from their conception and production to their promotion, distribution, and ultimate sale. The firm's offerings include a diverse range of consumer health products, such as its own branded traditional Chinese medicines – spanning everything from over-the-counter medications to specific medicated and non-medicated treatments. Additionally, it supplies diagnostic equipment and various pharmaceutical goods. Beyond manufacturing, JBM (Healthcare) is also involved in the buying, selling, and reselling (wholesale and retail) of Chinese medicines. Its business activities extend to the trade of medical supplies and pharmaceuticals, as well as the sale of general health and herbal products. Established in 2020, the company's main operations are directed from its headquarters in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary entity of JBM Group (BVI) Limited.
Key people
Executive Chairman of the Board · since 2025
Kau Lap Lam
Vice President - Finance · since 2023
Ka Kin Wong
Vice President - Greater China Sales and E-commerce · since 2020
Lin Wang
Deputy General Manager - Proprietary Chinese Medicine Business · since 2020
Heung Kwan Cheng
Executive Director · since 2024
Executive Director · since 2025
Hoi Ki Leung
Operation Manager - Proprietary Chinese Medicine · since 2014
Chui Yee Lo
Senior Marketing Manager · since 2013
Company Secretary · since 2023
Hong Xi Xu
Non-Executive Director · since 2025
Kwok Chun Yeung
Non-Executive Director · since 2020
Kam Chiu Chan
Independent Non-Executive Director · since 2021
Shut Lee Lau
Independent Non-Executive Director · since 2021
Independent Non-Executive Director · since 2021
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||